A new vision for adeno-associated virus delivered gene therapies

An international collaboration of leading groups in gene therapy and vision science have developed an adeno-associated virus (AAV) genome-coupled immunomodulation strategy that helps cloak the AAV virus from unwanted immune responses and offers important insights into ocular inflammation. The research led by Harvard University, Harvard Medical School and including the University of Bristol is published in Science Translational Medicine.